Bioxyne (ASX:BXN) announced an upgrade to its FY26 EBITDA guidance, now projected at $16.5–$19 million, following a powerhouse first-half performance.
The life sciences company reported H1 revenue of $31.3 million, marking a staggering 149% year-on-year increase.
The growth was underpinned by an adjusted EBITDA of $8.3 million and a net profit after tax of $7.3 million, driven largely by improved margins and aggressive international scaling.
The company reached a landmark operational milestone with the production of the first Australian-made, GMP-certified MDMA capsules, a critical step for its psychedelic medicine pipeline.
Bioxyne doubled its clean room capacity and tripled its storage, bringing its total revenue capacity to over $250 million per year.
The Australian facility is now capable of producing six million MDMA pastilles monthly. Initial German shipments alone generated $2.7 million in H1 revenue.
To further facilitate European capital access, Bioxyne completed a dual listing on the Frankfurt Stock Exchange in late 2025.
Furthermore, construction has commenced on a new GMP manufacturing facility in the Scottish Borders, supported by a £0.8 million grant from South of Scotland Enterprise.
At the time of reporting, Bioxyne's share price was $0.061.